Mechanism of Action

Liraglutide is a once-daily GLP-1 derivative for the treatment of type 2 diabetes. The prolonged action of liraglutide is achieved by attaching a fatty acid molecule at position 26 of the GLP-1 molecule, enabling it to bind reversibly to albumin within the subcutaneous tissue and bloodstream and be released slowly over time. Binding with albumin results in slower degradation and reduced elimination of liraglutide from the circulation by the kidneys compared to GLP-1. The effect of liraglutide is the increased secretion of insulin and decreased secretion of glucagon in response to glucose as well as slower gastric emptying. Liraglutide also does not adversely affect glucagon secretion in response to low blood sugar.

Class of Compound

Peptide

Street Names

Liraglutide, Saxenda

Effects

• Fat Loss
• Slower Digestion
• Feeling Fuller

Side Effects and Dangers

• Medullary Thyroid Carcinoma
• Acute Kidney Injury

Top Studies

• A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
• Liraglutide for weight management: a critical review of the evidence